CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)
Helen J. MacKay, Anna V. Tinker, Brad H. Nelson, Dmitriy Zamarin et autres
OBJECTIVE: IPROC is an ongoing platform trial investigating novel immunotherapy combinations in platinum resistant high grade serous ovarian cancer. Here we report on the combination of durvalumab with two conditionally active biologic antibody drug conjugates linked to monomethyl auristatin E: mecbotamab vedotin …
ca, us (code pays fourni par la source)